More than tripled risk of five-year mortality seen with use of complementary and alternative medicine alone compared with traditional therapies.

A unanimous United States Supreme Court decision has now removed a significant procedural hurdle for medical malpractice plaintiffs in 28 states. In this case, the Court was asked to determine whether ...

The FDA is expected to decide on treatments for ADHD, Alzheimer disease, breast cancer, diabetes, and myasthenia gravis.

The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.

The new advice comes as federal dietary guidance has taken a much different stance. Health officials, alongside US Health Secretary Robert F. Kennedy Jr., have suggested people can include more red ...

Three-year disease-free survival was 86.3% in the atezolizumab-mFOLFOX6 group vs 76.2% in the mFOLFOX6-alone group.

Incidence of primary end point lower for patients with target LDL level less than 55mg/dL vs less than 70mg/dL.

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. GZR4 (Gan ...

In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.

More participants felt "much more" in control of their diabetes, eating, and weight after switching to tirzepatide vs escalating dulaglutide. HealthDay News — For adults with type 2 diabetes (T2D) who ...

The Food and Drug Administration (FDA) has granted Fast Track designation to CDI-988 for treatment and prophylaxis of norovirus infection.

The Food and Drug Administration (FDA) has approved extended dosing intervals for Eylea HD ® (aflibercept) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ...